Finally, CTLA4Ig Graduates to the Clinic

Overview

Journal J Clin Invest

Specialty General Medicine

Date 1999 May 4

PMID 10225963

Citations 13

Authors

M H Sayegh

Affiliations

Soon will be listed here.

Citing Articles

CTLA-4Ig (abatacept) balances bone anabolic effects of T cells and Wnt-10b with antianabolic effects of osteoblastic sclerostin.

Roser-Page S, Vikulina T, Weiss D, Habib M, Beck Jr G, Pacifici R Ann N Y Acad Sci. 2018; 1415(1):21-33.

PMID: 29500936 PMC: 5867252. DOI: 10.1111/nyas.13643.

Bone and the Immune System.

Weitzmann M Toxicol Pathol. 2017; 45(7):911-924.

PMID: 29046115 PMC: 5749254. DOI: 10.1177/0192623317735316.

Physiological and pathophysiological bone turnover - role of the immune system.

Weitzmann M, Ofotokun I Nat Rev Endocrinol. 2016; 12(9):518-32.

PMID: 27312863 PMC: 5857945. DOI: 10.1038/nrendo.2016.91.

CTLA-4Ig-induced T cell anergy promotes Wnt-10b production and bone formation in a mouse model.

Roser-Page S, Vikulina T, Zayzafoon M, Weitzmann M Arthritis Rheumatol. 2014; 66(4):990-9.

PMID: 24757150 PMC: 3994890. DOI: 10.1002/art.38319.

The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis.

Weitzmann M Scientifica (Cairo). 2013; 2013:125705.

PMID: 24278766 PMC: 3820310. DOI: 10.1155/2013/125705.

References

Tivol E, Borriello F, Schweitzer A, Lynch W, Bluestone J, Sharpe A . Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995; 3(5):541-7. DOI: 10.1016/1074-7613(95)90125-6. View

Konieczny B, Dai Z, Elwood E, Saleem S, Linsley P, Baddoura F . IFN-gamma is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways. J Immunol. 1998; 160(5):2059-64. View

Bluestone J . Is CTLA-4 a master switch for peripheral T cell tolerance?. J Immunol. 1997; 158(5):1989-93. View

Chandraker A, Russell M, Willett T, Sayegh M . T-cell costimulatory blockade in experimental chronic cardiac allograft rejection: effects of cyclosporine and donor antigen. Transplantation. 1997; 63(8):1053-8. DOI: 10.1097/00007890-199704270-00002. View

Noel P, Boise L, Green J, Thompson C . CD28 costimulation prevents cell death during primary T cell activation. J Immunol. 1996; 157(2):636-42. View

Waterhouse P, Penninger J, Timms E, Wakeham A, Shahinian A, Lee K . Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995; 270(5238):985-8. DOI: 10.1126/science.270.5238.985. View

Issazadeh S, Zhang M, Sayegh M, Khoury S . Acquired thymic tolerance: role of CTLA4 in the initiation and maintenance of tolerance in a clinically relevant autoimmune disease model. J Immunol. 1999; 162(2):761-5. View

Dai Z, Konieczny B, Baddoura F, Lakkis F . Impaired alloantigen-mediated T cell apoptosis and failure to induce long-term allograft survival in IL-2-deficient mice. J Immunol. 1998; 161(4):1659-63. View

Sayegh M, Akalin E, Hancock W, Russell M, Carpenter C, Linsley P . CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med. 1995; 181(5):1869-74. PMC: 2192009. DOI: 10.1084/jem.181.5.1869. View

10.

Walunas T, Lenschow D, Bakker C, Linsley P, Freeman G, Green J . Pillars article: CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994. 1: 405-413. J Immunol. 2011; 187(7):3466-74. View

11.

Khoury S, Akalin E, Chandraker A, Turka L, Linsley P, Sayegh M . CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol. 1995; 155(10):4521-4. View

12.

Abrams J, Lebwohl M, Guzzo C, Jegasothy B, Goldfarb M, GOFFE B . CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest. 1999; 103(9):1243-52. PMC: 408469. DOI: 10.1172/JCI5857. View

13.

Reiser H, Stadecker M . Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med. 1996; 335(18):1369-77. DOI: 10.1056/NEJM199610313351807. View

14.

Linsley P, Brady W, Urnes M, Grosmaire L, Damle N, Ledbetter J . CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991; 174(3):561-9. PMC: 2118936. DOI: 10.1084/jem.174.3.561. View

15.

Perez V, Van Parijs L, Biuckians A, Zheng X, Strom T, Abbas A . Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity. 1997; 6(4):411-7. DOI: 10.1016/s1074-7613(00)80284-8. View

16.

Judge T, Tang A, Spain L, Sayegh M, Turka L . The in vivo mechanism of action of CTLA4Ig. J Immunol. 1996; 156(6):2294-9. PMC: 2849296. View

17.

Judge T, Wu Z, Zheng X, Sharpe A, Sayegh M, Turka L . The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J Immunol. 1999; 162(4):1947-51. View

18.

Sayegh M, Turka L . The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med. 1998; 338(25):1813-21. DOI: 10.1056/NEJM199806183382506. View

19.

Van Parijs L, Abbas A . Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science. 1998; 280(5361):243-8. DOI: 10.1126/science.280.5361.243. View

20.

Larsen C, Elwood E, Alexander D, Ritchie S, Hendrix R, Tucker-Burden C . Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996; 381(6581):434-8. DOI: 10.1038/381434a0. View